These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 21976574)
41. Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors. Edwards T; Allen E; Harding-Esch EM; Hart J; Burr SE; Holland MJ; Sillah A; West SK; Mabey D; Bailey R PLoS Negl Trop Dis; 2014 Aug; 8(8):e3098. PubMed ID: 25165994 [TBL] [Abstract][Full Text] [Related]
42. Population coverage and factors associated with participation following a mass drug administration of azithromycin for trachoma elimination in Amhara, Ethiopia. Ebert CD; Astale T; Sata E; Zerihun M; Nute AW; Stewart AEP; Gessese D; Ayenew G; Ayele Z; Melak B; Chanyalew M; Gashaw B; Tadesse Z; Callahan EK; Jenness SM; Nash SD Trop Med Int Health; 2019 Apr; 24(4):493-501. PubMed ID: 30674087 [TBL] [Abstract][Full Text] [Related]
43. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. Atik B; Thanh TT; Luong VQ; Lagree S; Dean D JAMA; 2006 Sep; 296(12):1488-97. PubMed ID: 17003397 [TBL] [Abstract][Full Text] [Related]
44. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Chern KC; Shrestha SK; Cevallos V; Dhami HL; Tiwari P; Chern L; Whitcher JP; Lietman TM Br J Ophthalmol; 1999 Dec; 83(12):1332-5. PubMed ID: 10574809 [TBL] [Abstract][Full Text] [Related]
45. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin. Edwards T; Harding-Esch EM; Hailu G; Andreason A; Mabey DC; Todd J; Cumberland P Trop Med Int Health; 2008 Apr; 13(4):556-65. PubMed ID: 18282237 [TBL] [Abstract][Full Text] [Related]
46. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Bailey RL; Arullendran P; Whittle HC; Mabey DC Lancet; 1993 Aug; 342(8869):453-6. PubMed ID: 8102427 [TBL] [Abstract][Full Text] [Related]
47. Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study. Tilahun Z; Fenta TG BMC Ophthalmol; 2018 Aug; 18(1):193. PubMed ID: 30081851 [TBL] [Abstract][Full Text] [Related]
48. Three-day course of oral azithromycin vs topical oxytetracycline/polymyxin in treatment of active endemic trachoma. Guzey M; Aslan G; Ozardali I; Basar E; Satici A; Karadede S Jpn J Ophthalmol; 2000; 44(4):387-91. PubMed ID: 10974295 [TBL] [Abstract][Full Text] [Related]
49. A Cross-Sectional Study of the Availability of Azithromycin in Local Pharmacies and Associated Antibiotic Resistance in Communities in Kilosa District, Tanzania. Ansah D; Weaver J; Munoz B; Bloch EM; Coles CL; Lietman T; West SK Am J Trop Med Hyg; 2019 May; 100(5):1105-1109. PubMed ID: 30915951 [TBL] [Abstract][Full Text] [Related]
50. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Fry AM; Jha HC; Lietman TM; Chaudhary JS; Bhatta RC; Elliott J; Hyde T; Schuchat A; Gaynor B; Dowell SF Clin Infect Dis; 2002 Aug; 35(4):395-402. PubMed ID: 12145722 [TBL] [Abstract][Full Text] [Related]
51. Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control. Bloch EM; West SK; Mabula K; Weaver J; Mrango Z; Munoz B; Lietman T; Coles C Am J Trop Med Hyg; 2017 Sep; 97(3):815-818. PubMed ID: 28722638 [TBL] [Abstract][Full Text] [Related]
52. Mass drug administration for trachoma: how long is not long enough? Jimenez V; Gelderblom HC; Mann Flueckiger R; Emerson PM; Haddad D PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003610. PubMed ID: 25799168 [TBL] [Abstract][Full Text] [Related]
54. Coverage assessment survey following trachoma mass drug administration (MDA) in six districts of Oromia, Western Ethiopia, 2017. Bekuma TT; Mosisa Kebebew G; Desalegn Waktole Z; Markos Cafo J; Wirtu D; Gaddisa S PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007924. PubMed ID: 31841516 [TBL] [Abstract][Full Text] [Related]
55. Acceptability of azithromycin for the control of trachoma in Northern Tanzania. Desmond N; Solomon AW; Massae PA; Lema N; Anemona A; Foster A; Mabey DC Trans R Soc Trop Med Hyg; 2005 Sep; 99(9):656-63. PubMed ID: 15979657 [TBL] [Abstract][Full Text] [Related]
56. Outcome of azithromycin treatment of active trachoma in Omani school children. Khandekarf R; Mohammed AJ East Mediterr Health J; 2003; 9(5-6):1026-33. PubMed ID: 16450533 [TBL] [Abstract][Full Text] [Related]
57. A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children. Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; Zhou Z; Bailey RL; Mabey DC; Porco TC; Keenan JD; Gaynor BD; West SK; Lietman TM Clin Infect Dis; 2017 Mar; 64(6):743-750. PubMed ID: 27956455 [TBL] [Abstract][Full Text] [Related]
58. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Batt SL; Charalambous BM; Solomon AW; Knirsch C; Massae PA; Safari S; Sam NE; Everett D; Mabey DC; Gillespie SH Antimicrob Agents Chemother; 2003 Sep; 47(9):2765-9. PubMed ID: 12936971 [TBL] [Abstract][Full Text] [Related]